Calamagrostis arundinacea Extract Mitigates Testosterone Induced Prostatic Hyperplasia in Rats
Open Access
- 11 March 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (3) , 453
Abstract
Background: Benign prostatic hyperplasia (BPH) is an age-associated urological condition defined by abnormal multiplication of both stromal and epithelial components within the prostate. Calamagrostis arundinacea (CA), a species of perennial grass native to East Asia, has been recognized for its anti-inflammatory and antioxidant biological activities. The present study examined whether CA extract could attenuate prostatic enlargement induced by testosterone propionate (TP) in rats. Methodology: To establish the experimental model, rats received subcutaneous TP injections (3 mg/kg/day) for four consecutive weeks. During the same period, an extract of CA (150 mg/kg/day) was orally administered. Results: TP-treated animals developed significant prostatic enlargement, whereas CA supplementation markedly reduced prostate weight and significantly decreased circulating dihydrotestosterone (DHT) and testosterone levels. Microscopic analysis demonstrated that CA mitigated glandular epithelial thickening and suppressed hyperplastic alterations. In addition, CA reduced proliferating cell nuclear antigen (PCNA) expression and increased apoptotic cell numbers, as evidenced by TUNEL staining. Gene expression analysis further revealed significant downregulation of insulin-like growth factor-2 (Igf-2), transforming growth factor-β (Tgf-β), and vascular endothelial growth factor (Vegf), in CA-treated prostates. Moreover, CA inhibited activation of the PI3K/Akt/mTOR signaling cascades by reducing phosphorylation of Akt and mTOR. Conclusions: Overall, these results indicate that CA extract alleviates testosterone-induced BPH through suppression of growth-related signaling cascades and induction of apoptosis, suggesting its potent value as a phytotherapeutic strategy for BPH management.Keywords
This publication has 62 references indexed in Scilit:
- Epigallocatechin‐3‐Gallate Attenuates Benign Prostatic Hyperplasia Development via Regulating Firmicutes to Inhibit Gastric Secretion of Insulin‐Like Growth Factor‐1Cell Biology International, 2025
- Pathophysiology of clinical benign prostatic hyperplasiaAsian Journal of Urology, 2017
- Photosynthesis and growth response of Calamagrostis arundinacea and C. villosa to enhanced UV-B radiationPhotosynthetica, 2006
- Phytotherapy for benign prostatic hyperplasiaCurrent Urology Reports, 2002
- Insulin‐like growth factors and risk of benign prostatic hyperplasia†The Prostate, 2002
- Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasiaWorld Journal of Urology, 2002
- Sex hormone-induced prostatic carcinogenesis in the Noble rat: The role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancerThe Prostate, 1998
- Review of the role of androgenic hormones in the epidemiology of benign prostatc hyperplasia and prostate cancerUrology, 1994
- Haematological and hepatotoxic effects of silken styles of corn in albino ratsJournal of Applied Toxicology, 1992
- Growth factors in the human prostateThe Journal of Steroid Biochemistry and Molecular Biology, 1991